🇺🇸 FDA
Pipeline program

Balstilimab, CR6086, CR6086

CR6086-1-04

Phase 2 small_molecule active

Quick answer

Balstilimab, CR6086, CR6086 for Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers is a Phase 2 program (small_molecule) at Pharm Research Associates (UK) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharm Research Associates (UK) Limited
Indication
Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials